The Gut Microbiome and Menopause: Exploring the Connection

Menopause marks a major physiological transition characterized by declining ovarian hormone production, particularly estrogen and progesterone. Alongside reproductive changes, menopause influences systemic physiology — including the gut microbiome, the complex microbial community in the gastrointestinal tract. Emerging evidence suggests a bidirectional relationship in which hormonal changes alter microbial composition and microbial activity can modulate estrogen metabolism and related health outcomes.

Estrogen metabolism in the gut is mediated in part by a subset of bacteria known as the estrobolome. These microbes produce enzymes such as β-glucuronidase that deconjugate estrogen metabolites, enabling their reabsorption into circulation. Altered estrobolome activity can therefore change circulating estrogen availability and may influence the severity of menopausal symptoms as well as long-term risks linked to estrogen deficiency.

Menopause-associated microbial shifts reported in human studies include reduced overall diversity and changes in taxonomic composition. Postmenopausal profiles often show lower abundance of SCFA-producing Firmicutes such as Ruminococcus and higher relative abundance of taxa like Prevotella, Dorea and Sutterella. These shifts are functionally relevant: reductions in short-chain fatty acid (SCFA) producers can impair gut barrier integrity and increase low-grade inflammation, while changes in amino acid and phenolic compound degradation pathways may affect metabolic homeostasis.

The microbiome’s functional pathways intersect with several menopause-relevant outcomes:

• Bone health: Gut microbes influence nutrient absorption, immune signaling and estrogen metabolism — all factors that affect bone remodeling. Dysbiosis may exacerbate postmenopausal bone density loss and contribute to osteoporosis risk.

• Cardiometabolic risk: Menopause-related alterations in microbial composition and function have been associated with adverse lipid profiles, increased systemic inflammation and changes in metabolites implicated in cardiovascular disease.

• Weight and metabolism: Certain shifts, for example increased Prevotella abundance, correlate with metabolic disturbances and higher obesity risk in some cohorts of postmenopausal women.

• Brain and mood: Through the gut–brain axis, microbial metabolites and immune mediators can influence mood, cognition and sleep; dysbiosis during menopause may therefore contribute to mood swings, anxiety or cognitive complaints reported during this life stage.

Practical strategies to support a resilient gut microbiome during menopause focus on diet and lifestyle. Emphasize a diverse, plant-forward diet rich in fermentable fibers to promote SCFA production; include fermented foods and other sources of live cultures alongside prebiotic-rich vegetables to support beneficial taxa. Limiting highly processed foods and added sugars helps prevent overgrowth of potentially harmful microbes. Regular physical activity is also associated with favorable microbial diversity and metabolic effects. For those interested in monitoring changes, validated laboratory options exist to characterize microbial composition and function (microbiome test).

Ongoing research continues to clarify which interventions reliably restore beneficial estrobolome functions and which microbial signatures predict health outcomes. For broader context on microbiome research and initiatives, see the EU project on diet–microbiome interactions (EU NUTRIOME Project) and an overview of gut microbiota basics (What is Gut Microbiota and Why Does It Matter). For a focused review of menopause-specific findings, consult the InnerBuddies article InnerBuddies: The Gut Microbiome and Menopause.

As evidence accrues, integrating microbiome-aware approaches with established clinical care may help mitigate some menopause-related risks while supporting overall health.